Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on CRNX stock, giving a Buy rating on May 30.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight the potential for Crinetics Pharmaceuticals to create significant value in the future. Despite a challenging start to the year with disappointing data for atumelnant in congenital adrenal hyperplasia, Schwartz remains optimistic about the company’s prospects, particularly with the upcoming PDUFA date for paltusotine in acromegaly and the EMA decision expected in the first half of 2026.
Crinetics is advancing several late-stage studies, including a Phase 3 trial for paltusotine in carcinoid syndrome and multiple studies for atumelnant in different conditions. Additionally, the company is developing CRN09682 for neuroendocrine tumors and other promising programs in the pipeline. These efforts, combined with the company’s strong drug development platform, present multiple opportunities for growth and value creation, making it an attractive investment opportunity.
In another report released on May 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $81.00 price target.